The American Society of Retina Specialists (ASRS) is holding a virtual Annual Meeting this year, which will run for four days from this Friday.
On Saturday, David Boyer, MD, will be presenting Opthea’s Phase 2a DME trial results including primary and secondary outcomes - “Switching to Combination OPT-302 with Aflibercept from prior AntiVEGF-A Monotherapy in Eyes with Persistent Diabetic Macula Edema (DME)”.
Dr. David Boyer, a Senior Partner at Retina Vitreous Associates Medical Group, Los Angeles, and Clinical Professor at the University of Southern California Roski Eye Institute, Keck School of Medicine, was a study investigator on the trial.
https://www.asrs.org/content/documents/asrs-2020-annual-meeting-program_6.9.20.pdf
https://www.managedhealthcareexecutive.com/view/is-combination-therapy-on-the-horizon-in-dme
Ann: Opthea Reports Positive Ph2a Trial Results of OPT-302 in DME, page-125
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
47.0¢ |
Change
0.025(5.62%) |
Mkt cap ! $578.6M | |||
| Open | High | Low | Value | Volume |
| 44.0¢ | 47.0¢ | 42.5¢ | $1.327M | 2.960M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 63945 | 46.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 47.0¢ | 88685 | 4 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| OPT (ASX) Chart |